RAF-1 Inhibitors
2 drugsAbout RAF-1
RAF-1, also known as c-Raf, is a serine/threonine kinase and a key component of the RAS-RAF-MEK-ERK signaling pathway, which regulates cell growth, proliferation, differentiation, and survival.
RAF-1 is a drug development target due to its central role in the RAS-RAF-MEK-ERK pathway, which is frequently dysregulated in diseases; however, there is currently no genetic evidence directly linking RAF-1 to specific diseases.
RAF-1 is targeted by two FDA-approved drugs: STIVARGA and VOXZOGO. These drugs are either small molecules or peptides and are developed by Bayer and BIOMARIN PHARM for other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Hypochondroplasia with only 3 trials.
- Emerging modalities (Peptide) signal innovation opportunity.
Top RAF-1 Drugs
The competitive landscape includes two companies with approved drugs: Bayer and BIOMARIN PHARM.
Low market concentration suggests relatively low barriers to entry for new RAF-1 targeted therapies.
RAF-1 Drug Modality Landscape
Modalities
Routes of Administration
RAF-1 is primarily targeted by small molecule modalities (50% of approved drugs).
The balanced modality landscape suggests opportunities for novel modalities like antibodies or PROTACs.
📈 Modality Evolution
Small molecules pioneered RAF-1 targeting (2012), with peptides entering more recently (2021).
RAF-1 Clinical Trials 231 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 64 | 39 | 10 | 14 | 80% |
| Phase 2 | 134 | 47 | 22 | 64 | 68% |
| Phase 3 | 29 | 13 | 6 | 9 | 68% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved RAF-1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting RAF-1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
RAF-1 Drug Approval Timeline (2012 - 2021)
The first RAF-1 targeted drug was approved in 2012, with the most recent approval in 2021.
A 10-year span between approvals indicates a potentially unsaturated market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 232 clinical trials targeting RAF-1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities